Dane Leone
Stock Analyst at Raymond James
(1.62)
# 3,077
Out of 4,825 analysts
88
Total ratings
36.76%
Success rate
-6.3%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.76 | +429.66% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $9.87 | +355.93% | 2 | Feb 21, 2024 | |
| BPMC Blueprint Medicines | Maintains: Strong Buy | $85 → $100 | $99.34 | +0.66% | 9 | Dec 22, 2023 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $40.64 | -26.18% | 1 | Nov 16, 2023 | |
| BLUE bluebird bio | Maintains: Outperform | $200 → $260 | $4.06 | +6,303.94% | 6 | Nov 8, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $590.00 | +61.02% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.06 | +532.60% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $38.53 | +19.40% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $26.78 | +157.65% | 5 | May 8, 2023 | |
| RLAY Relay Therapeutics | Upgrades: Strong Buy | $29 | $3.29 | +781.46% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $8 | $1.82 | +339.56% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $29 → $14 | $8.55 | +63.74% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $10.86 | +434.07% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $33.75 | +107.41% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.71 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $43.03 | +46.41% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $49.61 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.48 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $50.40 | +28.97% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.49 | - | 5 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $283.78 | -10.14% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.58 | +793.85% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $154.46 | - | 2 | Jul 21, 2017 |
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.76
Upside: +429.66%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $9.87
Upside: +355.93%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85 → $100
Current: $99.34
Upside: +0.66%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $40.64
Upside: -26.18%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200 → $260
Current: $4.06
Upside: +6,303.94%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $590.00
Upside: +61.02%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.06
Upside: +532.60%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $38.53
Upside: +19.40%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $26.78
Upside: +157.65%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.29
Upside: +781.46%
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $1.82
Upside: +339.56%
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.55
Upside: +63.74%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $10.86
Upside: +434.07%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $33.75
Upside: +107.41%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.71
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $43.03
Upside: +46.41%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $49.61
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.48
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $50.40
Upside: +28.97%
Dec 1, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $7.49
Upside: -
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $283.78
Upside: -10.14%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.58
Upside: +793.85%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $154.46
Upside: -